Mark Lowdell

Company: Inmune Bio, Inc

Job title: Chief Scientific Officer

Seminars:

Discussing Approaches when Developing an NK Product Potency Assay to Ensure Compliance 9:30 am

Explore how potency is defined for NK cell therapies, including the critical factors that influence their therapeutic effectiveness Discuss best practices for designing robust and reproducible potency assays, including selection of appropriate biological endpoints and assay methodologies Identify and discuss common challenges in developing NK product potency assays, including troubleshooting and optimizing assay performanceRead more

day: Day 2 AM

Industry Leader’s Fireside Chat: Discussing Present Advancements & Challenges in the Natural Killer Space to Envision the Future of NK Therapy 8:30 am

Discussing key advancements in the NK space to highlight the therapeutic potential of NK biology Sharing the latest findings in NK therapy and what this means for this field What are the biggest hurdles in this space that still need to be overcome?Read more

day: Day 1 AM

In Vivo activation of mINK cells with INKmuneTM – Results from a Phase I-II Clinical Trial in Patients with Metastatic, Castration-Resistant Prostate Cancer 3:30 pm

Discussing interim clinical results from using a tumor cell “psuedokine” to activate and recruit NK cells to target solid tumors in vivo Highlighting key considerations when moving NK trials from tertiary to secondary clinical settingsRead more

day: Day 1 PM